In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Siemens Claims Top IVD Slot With $7 Billion Dade Behring Purchase

This article was originally published in The Gray Sheet

Executive Summary

Siemens' medical unit solidified its status July 25 as the only company offering a comprehensive suite of both imaging and in vitro diagnostic products with its $7 billion acquisition of Dade Behring

You may also be interested in...

Siemens Makes First Molecular Dx Buy In Nine Years

The firm's health-care division bought private next-generation sequencing firm NEO New Oncology for an undisclosed amount.

M&A Ahead: Ten Potential Medtech Takeover Targets

Device firms have already been active with M&A deals in 2014. Here are 10 companies to look for as potential acquisition targets going forward.

IT Will Be Cornerstone In Personalizing Medicine, Siemens Says

Siemens has established itself as a leader in both imaging and in vitro diagnostics with the aid of recent multibillion-dollar acquisitions, but the company's ability to leverage its IT expertise will be critical to tie the pieces together, the firm says

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts